Iberdomide: The First-in-Class CELMoD Turns Protein Disposal Into Therapy

Article

One of the most interesting new ideas in cancer treatment comes from one of medicine’s most infamous drugs. Thalidomide was introduced in the 1950s as a sedative and later used for morning sickness. Its devastating effects on fetal development led to its withdrawal and helped reshape modern drug regulation. But thalidomide had another biological effect that wasn't understood at the time. Decades later, it was found to have significant activity against multiple myeloma. The explanation eventually led researchers to cereblon, or CRBN. Cereblon is part of the machinery cells use to decide which proteins should be tagged with ubiquitin and sent to the proteasome for destruction. What researchers discovered was remarkable: thalidomide didn't simply turn cereblon on or off. It changed which proteins cereblon recognized. That observation opened an entirely new way of thinking about drugs. Instead of designing a drug only to block a disease-causing protein, what if we could convince the cell to destroy that protein instead? Iberdomide (Zenbexus) is the first FDA-approved drug in a new class called CELMoDs—cereblon E3 ligase modulators. It takes advantage of the same basic biology uncovered through thalidomide, but does so much more deliberately. When iberdomide binds cereblon, it promotes the destruction of two proteins called Ikaros and Aiolos. These proteins matter because they help maintain IRF4 and MYC, part of a survival program that multiple myeloma cells depend upon. So the basic idea is surprisingly straightforward: Iberdomide → cereblon → Ikaros and Aiolos destroyed → myeloma survival signals fall Their loss can also increase T-cell and natural-killer-cell activity, adding an immune component to the drug's effect. Why Destroy a Protein Instead of Blocking It? Most targeted drugs work by finding an important protein and inhibiting what it does. But that isn't always easy. Some disease-driving proteins don't have convenient binding pockets. Others develop mutations that allow them to escape inhibitors. And some proteins perform important functions simply by being present, even when one of their activities has been blocked. Protein degradation approaches the problem differently. Don't just stop the protein from working. Remove it. The drug doesn't have to build a new disposal system. The cell already has one. The challenge is directing that machinery toward the protein we want eliminated. That's what makes cereblon so interesting. The Opportunity—and the Risk Cereblon exists throughout the body. It isn't a myeloma-specific protein. That means the goal isn't simply to activate cereblon. The challenge is to change its targeting with extraordinary precision. Thalidomide demonstrated what can happen when the wrong proteins are affected. Its interaction with cereblon can lead to degradation of proteins important during embryonic development. Modern drug design therefore has to ask two questions: Did we destroy the protein we wanted? And just as importantly: What else did we destroy? New tools such as large-scale proteomics allow researchers to look across thousands of proteins and begin answering both questions. A Much Bigger Story Iberdomide is important because of what it represents. The progression from thalidomide to modern cereblon modulators shows how far pharmacology has moved: Thalidomide: an unexpected biological effect. Iberdomide: deliberately exploiting that biology. The future: potentially designing molecules that direct cellular disposal machinery toward entirely new disease-driving proteins. For decades, precision medicine has largely asked: What is driving this disease, and how can we block it? Targeted protein degradation asks: What is driving this disease—and can we make the cell get rid of it? That may turn out to be one of thalidomide's most unexpected legacies.